The Intercontinental Childhood ITP Study
We are seeking to enroll patients with newly diagnosed ITP to take part in a 2 year follow up study examining the frequency, severity and timing of major hemorrhage in ITP. 1000 patients will be enrolled world-wide.
Who can be enrolled?
- Age between 4 months and 20 years.
- Newly established diagnosis of ITP.
- Isolated thrombocytopenia with no clinically apparent associated
conditions or other causes of thrombocytopenia, e.g. systemic
lupus erythematosus.
- Patients can be followed up at any site (not necessarily at RCH)
When to notify?
As soon after diagnosis as possible. We will then contact the patient/family to seek consent.
How to notify a new patient:
Preferably notification would be made on the internet the data-form
Email or telephone would be fine too (see below)
We will also receive reports from the Emergency Department at RCH and the Haematology Laboratory, but we are very keen to ask doctors to also notify when a diagnosis is made.
What follow up is required?
Patients will need to be seen for data collection at 1, 6, 12 and 24 months. Other visits will be determined by clinical need. An FBE is required at these visits. Clinical details will be recorded on a form I will provide to the treating doctor for these visits.
Will patients be given any specific treatment?
No, this is a follow up study only. Treatment will be dictated wholly by their treating doctor.
Thank you for your help with this study.
Dr Michael Marks MBBS MD MPH FRACP
Senior Lecturer
Department of Paediatrics
Royal Children's Hospital
Flemington Road, Parkville. 3052
Telephone: +61 3 9345 5181.
Mobile: 0418-389-382
Fax: +61 3 9345 6667
Email: michael.marks@rch.org.au
